Stephen Hodi
Sharon Crowley Martin Chair in Melanoma · Mass General Brigham
Credentials: · · ·
History
- Present
- Present
- 1995–1997
1988–1992
Research
Improved survival with ipilimumab in patients with metastatic melanoma
New England Journal of Medicine · 2010 · First of 29 authors · Corresponding · 12,191 citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
New England Journal of Medicine · 2012 · 10,404 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 6,426 citations
60 papers
50 papers
49 papers
39 papers
- GD
34 papers
34 papers
- JW
33 papers
33 papers
Grants
- 2026–2031
- 2017–2028
Cancer Immune Monitoring and Analysis Center
National Cancer Institute · U24
PI · $18.4M · Dana-Farber Cancer Inst
- 1997–2026
Dana-Farber/Harvard Cancer Center
National Cancer Institute · P30
Project lead · $510.6K · Dana-Farber Cancer Inst
- 2019–2025
Biomaterials to Create T Cell Immunity
National Cancer Institute · U54
PI · $8.2M · Harvard University
Clinical trials
- 2015–2033
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Principal investigator · Active not recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
- 2015–2027
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
- 2014–2025
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
- 2010–2027
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)